Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses SAFEbody technology utilized to create masked ...

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...

Summit Therapeutics (SMMT) stock gains as Cantor Fitzgerald issues an Overweight rating highlighting the company's lead asset ...

Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including ...

a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co ...

Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.

February saw several changes on boards at biotechs, bringing a diverse wealth of experience to support these companies. Read ...

Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions: Our Bureau, Bengaluru Thursday, March 20, 2025, 14:15 Hrs [IST] Syngene International ...